When “It’s Not Alzheimer’s”: Why Canada’s Medical Community Must Deepen Its Understanding of FTD

Frontotemporal dementia (FTD) is one of the most misunderstood and under-recognized neurodegenerative diseases in Canada. For families, the journey to diagnosis is often long, confusing, and emotionally devastating. For medical professionals, it can be an uncomfortable clinical challenge; rare, complex, and lacking a single definitive diagnostic test during life. But that discomfort cannot become inaction.

If we are to truly support patients and families living with FTD, we must strengthen awareness, education, and clinical confidence across Canada’s healthcare system.

The Diagnostic Reality of FTD

Unlike many other medical conditions, the only way to accurately diagnose FTD is through genetic testing or examination of brain tissue after death (autopsy). That alone should signal how nuanced and complex this condition is.

FTD typically presents with an insidious onset, subtle personality shifts, executive dysfunction, language changes, or motor decline that gradually worsen over time. It is not simply “memory loss,” and that distinction is critical. Too often, patients are misdiagnosed with psychiatric disorders, midlife crises, or atypical Alzheimer’s disease.

When FTD is suspected, referral to a neurologist specializing in cognition and behavior, or a geriatric neuropsychologist is indicated. Yet in many parts of Canada, access to such specialists is limited, resulting in delayed diagnosis and prolonged distress for families.

The Importance of Thorough Medical Screening

FTD is a diagnosis that requires careful exclusion of other causes. Medical professionals should:

• Screen all patients for obstructive sleep apnea (OSA), as executive dysfunction and behavior changes are common in OSA

• Order blood work including:

  • Basic metabolic panel

  • CBC

  • RPR

  • ESR

  • B12 level

  • Thyroid studies

• Assess vascular risk factors

• Consider infections (including HIV), immune-based dementias, and neoplastic/paraneoplastic etiologies

  
  

These steps are not optional, they are essential safeguards against misdiagnosis.

And yet, many families report fragmented workups, incomplete investigations, or premature psychiatric labeling.

Neuropsychological Testing: More Than a Screening Tool

A full neuropsychological evaluation is critical when FTD is suspected. These multi-hour assessments provide a pattern of cognitive loss that can distinguish FTD from psychiatric conditions or other dementias.

Importantly:

• Some patients may perform within normal limits in early stages

• When primary progressive aphasia (PPA) is suspected, referral to a speech-language pathologist is warranted

• Behavioral variant FTD (bvFTD) may masquerade as mood or personality disorders

  
  

Without comprehensive testing, we risk minimizing or misunderstanding what families are witnessing every day.

Brain Imaging: What It Can and Cannot Tell Us

Brain imaging should be performed in all suspected FTD cases to rule out structural causes such as:

• Small vessel ischemia

• Subdural hematomas

• Tumors

• Hydrocephalus

  
  

MRI's can reveal the classic “knife-edge” atrophy of the frontal and anterior temporal lobes, often asymmetrical with relative sparing of posterior regions. However, emerging research shows parietal lobe atrophy in many genetic cases, complicating traditional expectations.

When an MRI is not tolerated, a CT scan may be used. If scans remain inconclusive, FDG-PET or SPECT imaging may provide additional insight, with FDG-PET being more specific but costly.

In Canada, access to advanced imaging varies widely by province. For a disease that disproportionately affects people in their 50s and 60s, often still working and raising families, timely access to appropriate imaging is not a luxury; it is a necessity.

Genetic Counseling: Not Just for Those With Family History

Anyone diagnosed with FTD should consider genetic counseling regardless of family history.

Why?

Because:

• A significant portion of people without known family history still have an identifiable genetic cause

• Genetic identification may provide access to clinical trials

• It informs family members about potential risk

  
  

In Canada, awareness of genetic counseling options remains inconsistent. Telehealth and sponsored testing programs exist but many clinicians and families are unaware of them. This gap is not benign. It directly affects patient care and research participation.

There Are No Approved Medications

There are currently no approved medications for FTD-specific features. Management is largely symptomatic and behavioral.

This makes multidisciplinary collaboration essential:

• Primary care physicians

• Cognitive/behavioral neurologists

• Psychiatrists

• Neuropsychologists

• Speech, occupational, and physical therapists

  
  

FTD patients function best in structured, consistent environments. Caregivers need behavioral management strategies as much as patients need clinical oversight. Without adequate provider education, families are left navigating these complexities alone.

Why Medical Knowledge in Canada Must Improve

FTD is uncommon, but not rare. It is one of the leading causes of dementia in people under 65. These are individuals in the prime of life.

Yet across Canada:

• Many primary care physicians report discomfort diagnosing FTD

• Access to cognitive specialty centers is inconsistent

• Misdiagnosis as psychiatric illness remains common

• Families experience prolonged diagnostic odysseys

• Post-mortem pathology expertise may be limited in general settings

  
  

A definitive diagnosis can only be confirmed through genetic testing or brain autopsy. For families, confirmation matters, not only emotionally, but for advancing research and understanding disease mechanisms such as tau protein aggregation.

When medical professionals lack familiarity, families feel dismissed. When referrals are delayed, opportunities for planning and support shrink. When genetic counseling is overlooked, entire families are left without crucial information.

An Empathetic Call to Action

Medical professionals in Canada are deeply committed to patient care. The challenge with FTD is not indifference, it is exposure, training, and system capacity.

But empathy must extend beyond bedside manner. It must include:

• Curiosity when symptoms don’t fit Alzheimer’s disease

• Willingness to refer early

• Commitment to comprehensive testing

• Openness to genetic counseling discussions

• Collaboration across specialties

  
  

FTD robs individuals of personality, language, judgment, and motor function. It transforms families long before it takes lives. Caregivers and patients deserve care that helps to recognize FTD sooner, investigate it thoroughly, and speak about it knowledgeably.

#FTDCanada #FrontotemporalDementia #FTDAwareness #YoungOnsetDementia #DementiaCare #MedicalEducation #Neurology #GeneticCounseling #CaregiverSupport #BrainHealth #HealthcareInCanada